TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07483632: A Phase 3 Study With an Open-Label Extension in Pediatric Participants to Evaluate the Safety, Efficacy, and Pharmacokinetics of Diroximel Fumarate and Dimethyl Fumarate for the Treatment of Relapsing Forms of Multiple S

Sponsor: Biogen · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 185 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT07483632 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07483632 Rescue Dossier →